Ocular Therapeutix Inc. (NASDAQ:OCUL) had its target price lifted by analysts at Royal Bank Of Canada from $30.00 to $32.00 in a research report issued on Tuesday. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 261.17% from the company’s current price.

OCUL has been the topic of several other reports. Zacks Investment Research cut shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Wednesday, October 12th. BTIG Research reaffirmed a “buy” rating and set a $18.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, July 26th. Finally, JMP Securities started coverage on shares of Ocular Therapeutix in a research note on Thursday, August 11th. They set an “outperform” rating and a $5.84 price target on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Ocular Therapeutix currently has a consensus rating of “Buy” and a consensus price target of $18.56.

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ:OCUL) opened at 8.86 on Tuesday. Ocular Therapeutix has a one year low of $4.04 and a one year high of $14.50. The company has a 50 day moving average of $6.44 and a 200-day moving average of $6.99. The firm’s market cap is $220.43 million.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.11. Ocular Therapeutix had a negative net margin of 2,346.47% and a negative return on equity of 56.23%. On average, equities research analysts predict that Ocular Therapeutix will post ($1.77) earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in OCUL. Credit Suisse AG raised its position in Ocular Therapeutix by 58.2% in the third quarter. Credit Suisse AG now owns 27,614 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 10,163 shares during the last quarter. Morgan Stanley raised its position in Ocular Therapeutix by 481.4% in the third quarter. Morgan Stanley now owns 573,309 shares of the biopharmaceutical company’s stock valued at $3,938,000 after buying an additional 474,703 shares during the last quarter. Northern Trust Corp raised its position in Ocular Therapeutix by 8.5% in the third quarter. Northern Trust Corp now owns 210,345 shares of the biopharmaceutical company’s stock valued at $1,445,000 after buying an additional 16,541 shares during the last quarter. Columbus Circle Investors raised its position in Ocular Therapeutix by 76.2% in the third quarter. Columbus Circle Investors now owns 491,204 shares of the biopharmaceutical company’s stock valued at $3,375,000 after buying an additional 212,419 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in Ocular Therapeutix by 1.1% in the third quarter. California State Teachers Retirement System now owns 37,939 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 400 shares during the last quarter. Institutional investors and hedge funds own 77.66% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

5 Day Chart for NASDAQ:OCUL

Receive News & Stock Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related stocks with our FREE daily email newsletter.